Meeting
2020 ASCO Virtual Scientific Program
Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).
Authors
Chana Weinstock
U.S. Food and Drug Administration, Silver Spring, MD
Chana Weinstock , PRADEEP BANDARU , Laura L Fernandes , Elaine Chang , Andrew Girvin , Shenghui Tang , Sundeep Agrawal , Daniel L. Suzman , Harpreet Singh , Michael Holman Brave , James Xu , Kirsten B. Goldberg , Amna Ibrahim , Marc Robert Theoret , Richard Pazdur , Julia A. Beaver
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5045)
DOI
10.1200/JCO.2020.38.15_suppl.5045
Abstract #
5045
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.
First Author: Gerard Zalcman
Poster
2021 ASCO Annual Meeting
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
First Author: Matthew Scott Ernst
Poster
2021 ASCO Annual Meeting
Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy.
First Author: Haniel alves Araujo
Poster
2019 ASCO Annual Meeting
Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.
First Author: Chana Weinstock